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PWZ-029  is  an  5 GABAA selective  inverse  agonist.
We  tested  PWZ-029,  on  its  own  and  with  scopolamine,  in two memory  paradigms.
It  improved  object  recognition  in  the  novel  object  recognition  test.
PWZ-029  was  ineffective  in  the  Morris  water  maze  test.
Testing  of  putative  procognitive  compounds  needs  use  of  a  variety  of models.
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a  b  s  t  r  a  c  t
Inverse  agonism  at the benzodiazepine  site  of  5 subunit-containing  GABAA receptors  is  an  attractive
approach  for  the  development  of putative  cognition-enhancing  compounds,  which  are  still far  from  clin-
ical application.  Several  ligands  with  binding  and/or  functional  selectivity  for 5 GABAA receptors  have
been  synthesized  and tested  in a few  animal  models.  PWZ-029  is  an 5 GABAA selective  inverse  ago-
nist  whose  memory  enhancing  effects  were  demonstrated  in  the  passive  avoidance  task  in rats  and  in
Pavlovian  fear  conditioning  in mice.  In the  present  study  we  investigated  the  effects  of  PWZ-029  admin-
istration  in  novel  object  recognition  test  and  Morris  water  maze,  in  normal  and  scopolamine-treated
rats.  All  the three  doses  of PWZ-029  (2,  5  and  10 mg/kg)  improved  object  recognition  after  the  24-h  delay
period, as  shown  by  signiﬁcant  differences  between  the  exploration  times  of  the novel  and  old  object,
and the  respective  discrimination  indices.  PWZ-029  (2 mg/kg)  also  successfully  reversed  the 0.3  mg/kgater maze scopolamine-induced  deﬁcit  in  recognition  memory  after  the  1-h  delay.  In  the Morris  water  maze  test,
PWZ-029  (5,  10  and  15  mg/kg)  did  not  signiﬁcantly  inﬂuence  swim  patterns,  either  during  ﬁve  acquisition
days  or  during  the  treatment-free  probe  trial.  PWZ-029  (2,  5 and  10  mg/kg)  also  proved  to  be  ineffective
in  the reversal  of the 1 mg/kg  scopolamine-induced  memory  impairment  in the  water  maze.  The  present
mixed  results  encourage  use of  a variety  of tests  and  experimental  conditions  in order  to increase  the
predictability  of  preclinical  testing  of selective  5 GABAA inverse  agonists.
© 2012 Elsevier B.V. All rights reserved.. Introduction
Classical benzodiazepines are positive allosteric modulators at
he benzodiazepine binding site of inhibitory GABAA receptors and
ave been widely used for half a century as anxiolytics, hypnotics,
yorelaxant and anticonvulsant drugs. Soon after introduction into
∗ Corresponding author. Tel.: +381 11 3951280; fax: +381 11 3972840.
E-mail address: miroslav@pharmacy.bg.ac.rs (M.M.  Savic´).
166-4328/$ – see front matter ©  2012 Elsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.bbr.2012.12.016clinical practice, their propensity to disrupt memory formation
was recognized and became the subject of thorough examina-
tion [1,2]. Many studies examining the nature and mechanisms
of such memory impairment eventually led to a discovery that
negative modulation at the same receptors could elicit an oppo-
site effect [3]. Negative modulators (i.e. inverse agonists) of the
benzodiazepine binding site decrease chloride ﬂux through the
GABAA receptor ion channel, resulting in a decrease of GABAergic
inhibition and increase of neuronal excitability. These molecu-
lar and neuronal mechanisms of inverse agonism are reﬂected
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ehaviorally in increased vigilance, but also anxiogenic and procon-
ulsant actions [4]. Hence, inverse agonists at the benzodiazepine
inding site were shown to concomitantly improve certain forms
f memory in animals [3,5] and in human volunteers [6] and elicit
onvulsant/proconvulsant and anxiogenic effects [7,8].
In the last two decades, genetic and pharmacological studies, by
he means of generation of mutant mouse lines [9] and synthesis of
ovel, subtype-selective ligands, respectively, have helped in link-
ng the particular behavioral response to a distinct GABAA receptor
ubtype [11–13]. Of the four GABAA receptor populations (1-,
2-, 3- and 5-GABAA receptors) that are sensitive to benzodi-
zepine modulation, those receptors containing 1 and 5 subunits
ere shown to be substantially involved in mediating their mem-
ry effects [10,14–17].  While the reduced expression of 5 GABAA
eceptors has been selectively linked to facilitation of some aspects
f cognition [14,15], inverse agonism at the 1 subunit was also
onnected with the emergence of proconvulsive and convulsive
ctivity [18,19], and hence GABAA receptors containing the 5 sub-
nit became an ultimate target for the development of putative
ognition-enhancing compounds [20].
Over the years, a number of compounds with binding and/or
unctional selectivity for 5 GABAA receptors have been synthe-
ized and tested in different animal models and species [21–24].
ost of them improved performance in memory tasks, whilst at the
ame time being devoid of CNS-mediated adverse effects [25–29].
n healthy humans, pre-treatment with an 5 efﬁcacy-selective
nverse agonist signiﬁcantly reduced the amnesic effect of alco-
ol on learning a word list, thus providing a valuable proof of the
oncept that 5 GABAA receptors play a principal role in mem-
ry processes [30]. However, to date there are no GABAA receptor
nverse agonists in the clinical practice, which indicates the need for
urther search for ligands with optimal efﬁcacy/safety proﬁle, that
ould translate into drugs with a clear-cut cognition enhancing
otential in humans [31].
PWZ-029 is a partial inverse agonist that binds with preferen-
ial afﬁnity to 5 GABAA receptors, while at 1- and 3-containing
eceptors exhibits weak agonistic activity. In a previous study,
WZ-029 improved passive but not active avoidance learning task
n rats, showed no effect on anxiety or muscle tone, and had no
onvulsive activity in the tested dose range (2–20 mg/kg) [23]. In
ice, PWZ-029 at a dose of 10 mg/kg was able to robustly attenuate
copolamine-induced impairment of Pavlovian fear conditioned
ontextual memory [32]. The aim of the present study was to test
WZ-029 in unimpaired animals as well as against a scopolamine-
nduced deﬁcit in Morris water maze (MWM)  and novel object
ecognition test (NORT), two paradigms widely used for behavioral
creening of putative memory enhancing compounds [33,34].
. Material and methods
.1. Animals
Male Wistar rats, weighing 200–230 g, were supplied by Military Farm, Belgrade,
erbia. Rats were housed in groups of four and were maintained under standard
aboratory conditions (21 ± 2 ◦C, relative humidity 40–45%) with free access to pellet
ood and tap water. They were kept on 12:12 h light/dark cycle with lights on at
7.00 h. All handling and testing took place during the light phase of the diurnal
ycle. Experiments were carried out in accordance with the EEC Directive 86/609
nd were approved by the Ethical Committee on Animal Experimentation of the
aculty of Pharmacy in Belgrade. Each of four experiments was performed using
eparate sets of experimentally naïve animals.
.2. DrugsPWZ-029, an 5 selective inverse agonist, was synthesized at the Department
f Chemistry and Biochemistry, University of Wisconsin–Milwaukee, USA. The
ompound was suspended in a vehicle containing 85% distilled water, 14% pro-
ylene glycol and 1% Tween-80, and administered intraperitoneally in a volume of
 ml/kg, 20 minutes before the testing. Scopolamine hydrobromide (Sigma–Aldrich,search 241 (2013) 206– 213 207
Germany) was  dissolved in saline and administered intraperitoneally in a volume
of  1 ml/kg, 30 min  before the testing.
2.3. Novel object recognition test
2.3.1. Apparatus and procedure
Novel object recognition test was  performed as described elsewhere [35]. The
apparatus consisted of a rectangular chamber (65 cm × 45 cm × 45 cm)  placed in a
room with a red dim illumination (∼20 lx). Animals were habituated to the empty
chamber for 10 min, 24 h before the beginning of experiment. Novel object recogni-
tion  test was divided in two phases, familiarization and testing. In the familiarization
phase two  identical objects were placed 15 cm from the sides of the chamber and
25  cm apart. After receiving appropriate treatment, each rat was placed in the arena
between the two  objects facing the opposite wall and allowed to explore them for
5  min. Animal was  then removed from the apparatus and returned to the cage (1 h)
or  to the colony (24 h) for the prescribed retention interval. To test for object recogni-
tion, one of the familiar sample objects was replaced with a novel object and animal
was returned to the apparatus and allowed to explore for 3 min. Object exploration
was  recorded when the animal was in close proximity (2 cm or less) and oriented
to the object, and if the animal sniffed or pawed the object. Object set consisted of
a  semi-transparent pyramid (base 8 cm × 8 cm,  height 7 cm)  and a nontransparent
dome-shaped paperweight (base diameter 9 cm, height 10 cm), which could not be
displaced by rats. Each object was  available in triplicate and all combinations and
locations of objects were used in a balanced manner to reduce potential biases due
to  preferences for particular locations or objects [36]. After each trial, the apparatus
and objects were cleaned with 70% ethanol to reduce olfactory cues.
2.3.2. Experiments
In the ﬁrst experiment, four groups of rats (n = 10) received vehicle or PWZ-029
(2,  5 or 10 mg/kg) 20 min  before familiarization phase. After 24 h, object recogni-
tion memory was  tested. In the second experiment we examined the inﬂuence of
PWZ-029 (2, 5 or 10 mg/kg) on the scopolamine-induced memory impairment in
NORT. The dose of scopolamine (0.3 mg/kg) was selected according to our prelimi-
nary testing (unpublished data). There were ﬁve group of rats (n = 12–15) and each
group received one of the following treatments before the familiarization phase:
saline + vehicle, scopolamine (0.3 mg/kg) + vehicle and scopolamine in combination
with PWZ-029 (2, 5 and 10 mg/kg). Retention interval was 1 h. Rats were monitored
using the Any-Maze video-tracking software. The amount of time exploring familiar
(T1) and novel (T2) objects was automatically scored, and then total time exploring
(T1 + T2) and discrimination index ((T2-T1)/(T1 + T2)) were calculated.
2.4. Morris water maze
2.4.1. Apparatus and procedure
Experiments were performed in a 2 m diameter circular pool ﬁlled to a height of
30  cm with water at 23 ◦C. The escape platform (15 cm × 10 cm) of the same color as a
pool  was submerged 2 cm below the water surface in the northeastern quadrant (NE
region) of the pool. An indirect illumination in the experimental room was provided
by  white neon tubes ﬁxed on the walls and many distal cues were present (doors,
pipes on the walls and the ceiling, cupboards, a camera suspended above the center
of  the maze). On each of the ﬁve consecutive days rats were given one swimming
block, consisting of two or four trials, depending on the experimental condition. Each
trial lasted a maximum time of 120 s, after which rat was  manually guided to the
platform and left there for 15 s. Between two consecutive trials, rats were returned
to  their cage and given a 60-s rest. Start positions varied pseudo-randomly among
the four cardinal points (W,  NW,  S, SE). During the acquisition phase, treatments
were applied once daily before the swimming block. On the sixth day, rats were
given a treatment–free probe trial (60 s) without the platform [37].
2.4.2. Experiments
In the ﬁrst experiment, we examined the inﬂuence of PWZ-029 administra-
tion on water maze performance in rats. Four groups of rats (n = 7) received vehicle
or PWZ-029 (5, 10 or 15 mg/kg). We used a two-trial per day protocol which
is  associated with diminished performance of control animals, thus allowing for
potential enhancement effects to be revealed [38]. In the second experiment, a
standard four-trial per day protocol was used and the inﬂuence of PWZ-029 on
scopolamine-induced impairment of water maze performance was assessed. The
dose of scopolamine (1 mg/kg) was selected based on our pilot data as the dose
that completely disrupted acquisition in MWM.  The animals were divided into ﬁve
groups (n = 8) and received one of the following treatments: saline + vehicle, scopol-
amine (1 mg/kg) + vehicle, and combination of scopolamine (1 mg/kg) and PWZ-029
(2,  5 and 10 mg/kg).
Animals were monitored with the Any-Maze (Stoelting, Wood Dale, USA) video
analysis system. The pool was virtually divided into four quadrants, three concentric
annuli and a target region consisting of the intersection of the platform quadrant and
the platform (middle) annulus, as represented in an earlier paper [17]. Dependent
variables chosen for tracking during the acquisition trials were: escape latency (s),
path efﬁciency (the ratio of the shortest possible path length to actual path length),
total distance travelled (m), distance in the peripheral ring (%) and swim speed
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m/s).  The indices of memory, assessed during the probe trial, included time in the
E region (s), time in the target zone (s) and time in the peripheral ring (s).
.5. Statistics
All numerical data presented in the ﬁgures are given as the mean ± S.E.M. The
ata from the acquisition days in the Morris water were averaged for each rat
total data/total number of trials per day) and analyzed using two-way ANOVA with
epeated measures. If the interaction between the day and treatment was  signiﬁ-
ant, then one-way ANOVA for the treatment effect for each day was performed. The
ata from the probe trial were assessed using one-way ANOVA. Post hoc compar-
sons, where applicable, were performed using Student–Newman–Keuls (SNK) test.
n  NORT, total exploration times of different treatment groups were analyzed using
ne-way ANOVA with post hoc SNK test. The differences between exploration times
pent with old and novel objects for each group were evaluated using paired t-test.
iscrimination index was  assessed by one-sample t-test per treatment group. Sta-
istical analysis was  performed using SigmaPlot 11 (Systat Software Inc., Richmond,
SA)  software. Differences were considered to be statistically signiﬁcant when p was
ess  than 0.05.
. Results
.1. Novel object recognition test
The effects of PWZ-029 administration on the rats’ behavior
n the novel object recognition test are depicted in Fig. 1. One-
ay ANOVA revealed no differences between total exploration
imes among different treatment groups (F(3,36) = 0.973, p = 0.416)
Fig. 1a). However, rats receiving 2, 5 and 10 mg/kg PWZ-029 spent
igniﬁcantly more time exploring the new object than the familiar
ne (t = −5.884, p < 0.001; t = −2.712, p = 0.024; t = −3.526, p = 0.006,
espectively), whereas rats treated with vehicle showed no signif-
cant difference (t = −1.264, p = 0.238) in the exploration time of
he familiar object compared with that of the novel one (Fig. 1b).
iscrimination indices (Fig. 1c) were signiﬁcantly different from
ero (i.e. chance level) for the rats treated with 2 mg/kg PWZ-029
t = 4.625; p = 0.001), 5 mg/kg PWZ-029 (t = 3.974; p = 0.003) and
0 mg/kg PWZ-029 (t = 3.670; p = 0.005), but not for the control
roup (t = 1.489; p = 0.171).
Fig. 2 shows effects of PWZ-029 administration on scopolamine-
retreated rats in NORT. Analysis of variance showed signiﬁcant
ffect of treatment on the total exploration time (F(4,65) = 3.167,
 = 0.019); post hoc SNK test revealed that rats injected with
ombination of 0.3 mg/kg scopolamine and 5 mg/kg PWZ-029
pent less time (p = 0.017) in exploring behavior compared to the
ontrol group as well as to group that received 0.3 mg/kg scopol-
mine + vehicle (p = 0.03) (Fig. 2a). Comparison of the times spent in
xploring familiar and novel object showed that only control group
nd group treated with combination of 0.3 mg/kg scopolamine
nd 2 mg/kg PWZ-029 spent signiﬁcantly more time in exploring
ew object (t = −2.276, p = 0.044; t = −3.106, p = 0.008, respectively)
Fig. 2b). Similarly, discrimination indices (Fig. 2c) were signif-
cantly different from zero for the control group (t = 2.522; p
 0.028) and group treated with combination of 0.3 mg/kg scopol-
mine and 2 mg/kg PWZ-029 (t = 2.552; p = 0.023).
.2. Morris water maze
The application of PWZ-029 during acquisition days did not
igniﬁcantly inﬂuence swim patterns in the Morris water maze
Table 1). None of the doses tested (5, 10 and 15 mg/kg) signiﬁ-
antly inﬂuenced any of the four indices of memory during training
ays: escape latency (Fig. 3a), path efﬁciency (Fig. 3b), total distance
ravelled (Fig. 3c) and percent of the distance in the peripheral ring
Fig. 3d). This reﬂected in performance during probe trial, where no
igniﬁcant differences were found among treatments in the time
pent in the NE region (Fig. 4a), time in the target zone (Fig. 4a) and
ime in the peripheral ring (Fig. 4b). Ta
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Fig. 1. The effects of PWZ-029 (2, 5 and 10 mg/kg) on (a) total exploration time,
(b) time exploring familiar and novel objects and (c) discrimination indices in the
novel object recognition test using a 24-h delay (mean + SEM). Signiﬁcant differences
from control (VEH) are indicated with asterisks (paired-samples t-test, *p < 0.05,
*
(
1
t
d
f
(
P
t
l
a
m
p
Fig. 2. The effects of 0.3 mg/kg scopolamine (SCOP 0.3) and combination of
0.3  mg/kg scopolamine and PWZ-029 (2, 5 and 10 mg/kg) on the rats’ performance
in  the object recognition task after a 1-h delay: (a) total exploration time, (b)
time exploring familiar and novel objects and (c) discrimination index. Data are
represented as mean + S.E.M. Signiﬁcant differences from control (SAL + VEH) are
indicated with asterisks (*p < 0.05 for one-way ANOVA on total exploration time
with post hoc SNK, and for paired-samples t-test for the familiar vs. novel exploration
+*p < 0.01, ***p < 0.001). A signiﬁcant difference from zero is indicated with hashes
one sample t-test, ##p < 0.01). Number of animals per each treatment group was
0.  VEH = vehicle.
In the second experiment, there were signiﬁcant effects of fac-
or treatment and factor day regarding all the parameters observed
uring acquisition (Table 1). After the post hoc analysis was per-
ormed, it appeared that all groups treated with scopolamine
scopolamine in combination with vehicle or 2, 5 and 10 mg/kg
WZ-029) increased escape latency compared to control (respec-
ive p values from SNK test: 0.009, 0.006, 0.019 and 0.019), and had
ower path efﬁciency (respective p values: <0.001, <0.001, <0.001
nd p = 0.002). The respective signiﬁcant differences among treat-
ents during days are presented in Fig. 5a and b. Scopolamine
retreatment was also a source of signiﬁcant variation amongtimes); p < 0.05 signiﬁcant difference from SOL + SCOP 0.3. A signiﬁcant difference
from zero is indicated with hashes (one sample t-test, #p < 0.05). Number of animals
per  each treatment group was 12–15. SAL = saline, VEH = vehicle.groups regarding the total distance travelled (Fig. 5c) and % of dis-
tance in the peripheral ring (Fig. 5d). Scopolamine increased total
distance compared to control (p = 0.005), and addition of PWZ-
029 did not inﬂuence this score since the groups treated with
210 M. Milic´ et al. / Behavioural Brain Research 241 (2013) 206– 213
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sig. 3. The inﬂuence of PWZ-029 (5, 10 and 15 mg/kg) on parameters related to lea
fﬁciency, (c) total distance travelled and (d) % of distance in the peripheral ring (m
ombination of scopolamine and PWZ-029 (2, 5 and 10 mg/kg) still
ad signiﬁcantly longer swim path than control group (respective
 values: 0.007, 0.002 and 0.005). Additionally, all scopolamine-
reated groups swam signiﬁcantly faster during acquisition days
data not shown).
In Fig. 6a, the time that rats spent in the platform quadrant (NE)
uring probe trial is presented alongside the respective time in the
ortion of NE quadrant lying in the platform annulus of the maze
‘the target region’). There were no signiﬁcant differences among
roups regarding time spent in the NE quadrant. However, there
as a signiﬁcant effect of treatment for the time spent in the tar-
et region (F(4, 35) = 2.682, p = 0.047). Post hoc test revealed that
ats treated with combination of scopolamine and 5 mg/kg PWZ-
29 spent signiﬁcantly less time in the target region (p = 0.043).
uring probe trial, groups also spent signiﬁcantly different times
n the peripheral ring (F(4,35) = 5.137, p = 0.002). Rats treated with
copolamine and rats treated with combination of scopolamine
nd PWZ-029 (2, 5 and 10 mg/kg) spent more time searching in
he peripheral ring compared to control. The respective differ-
nces (p = 0.003, p = 0.005, p = 0.004 and pp = 0.004) are presented
n Fig. 6b.
. Discussion
A substantial amount of preclinical research has focused on
dentifying compounds that may  improve different aspects of cog-
ition. Successful translation from promising in vitro properties
nto a clinically efﬁcacious and safe therapy has long been rec-
gnized as a major bottle-neck in this ﬁeld, which necessitates
creening of newer ligands and thorough assessment of their effectsin the 2-trial per day version of Morris water maze test: (a) escape latency, (b) path
 SEM). Number of animals per each treatment group was  7. VEH = vehicle.
in a diversity of the behavioral tasks in normal and experimentally
impaired laboratory animals [31,39].
PWZ-029 is one of the several inverse agonists whose selec-
tive afﬁnities and/or efﬁcacies at 5 GABAA receptor population
were set as a basic premise for their protective or therapeutic
action in various cognitive impairments, and whose positive results
in preclinical studies have already been published [40]. To date,
memory enhancing effects of PWZ-029 were demonstrated in the
passive avoidance task in rats and in Pavlovian fear conditioning
test in mice. At the same time, PWZ-029 proved to be devoid of
serious adverse effects such are anxiogenic and convulsive activ-
ity [23,32]. In the present study, PWZ-029 was tested in normal
and scopolamine-impaired rats using two  paradigms indicative of
different forms of memory, the novel object recognition test and
Morris water maze.
Object recognition test examines capability of animals to spon-
taneously discriminate between familiar and novel objects after the
prescribed retention interval. Normal rats accurately discriminate
between the novel and the familiar object after a 1-h but usually
not after a 24-h delay [41]. The delay-dependent decline in mem-
ory recognition is believed to be a result of failure of the perirhinal
cortex to maintain information about the object during longer
retention intervals [42,43]. In the present experiment, PWZ-029
was able to improve object recognition after a 24-h delay, which
is shown by the difference between exploration time of novel and
old objects as well as discrimination indices. The result is comple-
mentary to ﬁndings that both systemic and central (in the perirhinal
cortex) administration of benzodiazepines produced impairment in
object recognition task, indicating involvement of GABAergic neu-
rotransmission in regulation of this form of learning [44–46].  Since
the cited studies used nonselective agonists of the benzodiazepine
M. Milic´ et al. / Behavioural Brain Re
Fig. 4. Parameters of memory retention assessed during the drug-free probe trial,
in  animals previously treated with 5, 10 and 15 mg/kg PWZ-029: (a) time in the NE
quadrant and time in the target region (stripped bars) and (b) time in the peripheral
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On the other hand, PWZ-029 proved to be inefﬁcacious in Morrising. Data are represented as mean + S.E.M. Number of animals per treatment group
as  7. VEH = vehicle.
inding site, it remained unclear whether the impairment occurred
ue to activity at widespread 1 subunit-containing receptors or
t 5 GABA receptors, whose distribution is limited to the hip-
ocampus and certain cortical structures [47]. Results from our
tudy showed for the ﬁrst time that memory enhancement in the
bject recognition task can be achieved by systemic administration
f an 5 GABA selective inverse agonist to unimpaired rats, suggest-
ng the signiﬁcance of 5 GABA receptor population in this type of
emory. However, in order to conﬁrm the present results, addi-
ional experiments using full agonists and antagonists selective for
he 5 subunit would be worthwhile.
Scopolamine-induced cognitive impairment is frequently used
o model the memory, attention, and executive function-related
eﬁcits that are seen in aging and dementia [48]. In the NORT, rats
reated with scopolamine do not discriminate between the familiar
nd the novel object after a 1-h delay. The hypothesis that neg-
tive modulation of GABAA receptors could facilitate cholinergic
ransmission and thus improve cognitive functions is based on the
act that cholinergic pathways in certain brain regions involved in
earning/memory processes are under the strong inhibitory inﬂu-
nce of GABA neurons [49,50]. Results from our study supported
his hypothesis as PWZ-029 successfully reversed the scopolamine-
nduced deﬁcit in recognition memory after a 1-h delay. However,
nly the lowest dose of PWZ-029 (2 mg/kg) was  capable of shifting
he difference in time exploring novel vs. familiar objects and dis-
rimination index to the control levels. The inefﬁcacy of the twosearch 241 (2013) 206– 213 211
higher PWZ-029 doses (5 and 10 mg/kg) in this model could be
discussed from the point of possible nonspeciﬁc behavioral effects
of the combined treatment. For example, combination of scopol-
amine and 5 mg/kg PWZ-029, but neither of these treatments alone,
resulted in a signiﬁcant decrease of the total exploration time,
which may  have confounded the results.
Unlike NORT which measures cognitive capability, MWM  is
a paradigm which tests cognitive efﬁciency, i.e. it tests whether
treatment groups signiﬁcantly differ from control in efﬁciency to
ﬁnd a hidden platform (cf. Ref. [31]). In a delayed matching-to-
position version of MWM  task, which tests spatial working memory
(WM)  when the platform position changes every day, this dif-
ference is revealed through the saving times between the ﬁrst
and the second trial on each of the testing days. In this version
of the task, mice lacking the 5 GABAA receptor subunit [14], as
well as rats treated with inverse agonists at 5 GABAA recep-
tors [27], have been reported to have greater saving times than
control. In the protocol that tests reference memory (RM), how-
ever, position of the platform remains the same throughout the
days, and latency, distance and other related parameters are cal-
culated. In RM protocol, McNamara and Skelton [38] reported
improvement with the nonselective GABAA inverse agonist -
CCM. Nonetheless, rats treated with PWZ-029 remained at the
control level in the same protocol. The lack of efﬁcacy of an 5
GABAA receptor inverse agonist in the current experiment could
be considered in the light of the relative importance of the 5
and 1 modulation in the RM protocol. Our previous study [17]
suggested a greater contribution of the 1 than the 5 subunit-
containing GABAA receptors to the diazepam-induced impairment
in RM protocol, which clearly reduced probability of detecting
putative facilitating effects exerted via inverse agonism at the 5
subtype. Furthermore, although both WM and RM protocols mea-
sure spatial memory, they reﬂect distinct mnemonic processes,
which probably have distinct neurobiological mechanisms and
thus are susceptible to modulation to a different degree [51,52].
Since there are no other reports on the use of a selective 5
GABAA receptor inverse agonist in unimpaired animals in RM pro-
tocol, the suggested explanation needs to be conﬁrmed by further
research.
There are numerous examples where administration of a
cognition-enhancing drug exerted no measurable effects in normal
animals, whereas improved the measured cognitive parameters
in subjects with experimentally induced deﬁcits (reviewed in
Ref. [39]). In our study, however, this was  not the case, since
PWZ-029 failed to reverse the scopolamine-induced impairment
in MWM.  Hence, besides the previously shown lack of activity
of PWZ-029 on its own  in RM protocol, an overall inefﬁciency
of PWZ-029 in this experimental model may  be postulated. In a
similar experimental setup, it was shown that both, S8510 and
CGS8216, an inverse agonist and an antagonist at GABAA receptors,
reversed the scopolamine-induced deﬁcit in MWM  [53]. However,
the other nonselective inverse agonist, FG7142, that had been pre-
viously shown to improve short-term memory in unimpaired rats
[54], was  ineffective in this manner [53]. Taken together, these
examples with MWM  results imply a limited and substance- and
task-dependent potential of efﬁcacy of inverse agonists at GABAA
receptors.
In conclusion, our study showed for the ﬁrst time that an
inverse agonist at 5 GABAA receptors, PWZ-029, may  be efﬁca-
cious in improving performance in the novel object recognition test
in unimpaired rats, and also ameliorates deﬁcits in memory and
learning function induced by a muscarinic antagonist in this test.water maze, either alone or in reversing the scopolamine-induced
impairment. These results indicate that behavioral screening of
the putative cognition-enhancing compounds should include a
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Fig. 5. The effects of 1 mg/kg scopolamine (SCOP 1 + VEH) and combination of 1 mg/kg scopolamine and 2, 5 and 10 mg/kg PWZ-029 (SCOP 1 + PWZ-029 2, SCOP 1 + PWZ-029
5  and SCOP 1 + PWZ-029 10) on: (a) escape latency, (b) path efﬁciency, (c) total distance tr
the  water maze. *p < 0.05, **p  < 0.01, ***p < 0.001, compared to control (SAL + VEH); ++p < 0.
compared to SCOP 1 + PWZ-029 5. Number of animals per treatment was 8. SAL = saline, V
Fig. 6. The representative parameters of water-maze performance in the probe trial:
(a)  time spent in the NE quadrant and time spent in the target zone (stripped bars),
and (b) time in the peripheral ring. Data are represented as mean + S.E.M. *p < 0.05,
**p < 0.01, compared to control (SAL + VEH). Number of animals per treatment group
was  8. SAL = saline, VEH = vehicle.avelled and (d) % of distance in the peripheral ring during 5-day acquisition trials in
01 compared to SCOP 1 + VEH, #p < 0.05 compared to SCOP 1 + PWZ-029 2, Vp < 0.05
EH = vehicle.
variety of tests, models and experimental conditions in order to
increase the predictability of the sometimes erratic positive pre-
clinical results.
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